Drug Profile
Research programme: anticancer drug complex therapeutics - AptaBio Therapeutics/Samjin Pharmaceutical
Alternative Names: APTA-NewLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator AptaBio Therapeutics; Samjin Pharmaceutical Company
- Class Antineoplastics; Drug conjugates; Nucleotide aptamers
- Mechanism of Action Nucleolin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer